SOUTH ORANGE, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will be participating in the Benchmark Company 13th Annual Discovery One-on-One Investor Conference. The event is scheduled for Wednesday, December 11, 2024, at the New York Athletic Club in New York City.
Robert Banks, CEO and Judy Krandel, CFO of Nephros, Inc. will be hosting one-on-one and group investor meetings. If you would like to schedule a 1x1 investor meeting please make sure you are registered here:
The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which Nephros will be participating in one-on-one meetings with investors and analysts throughout the day.
About The Benchmark Company
The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. We were founded in 1988 and are headquartered in New York City. Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm’s sales, trading, and equity research capabilities. https://www.benchmarkcompany.com.
About Nephros
Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the needs of customers within the healthcare and commercial markets, offering both proactive and emergency solutions for water management.
For more information about Nephros, please visit us at nephros.com.
Investor Relations Contacts:
Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
This email address is being protected from spambots. You need JavaScript enabled to view it.
Robert Banks, CEO
Nephros, Inc.
(201) 343-5202 x110
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.95 |
| Daily Change: | -0.09 -4.41 |
| Daily Volume: | 22,418 |
| Market Cap: | US$20.550M |
November 07, 2024 October 24, 2024 November 08, 2023 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
